Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications

Celyad appoints Carri Duncan as Vice-President Corporate Development & Communications

Celyad to Participate at Upcoming Healthcare Conferences

Celyad to Participate at Upcoming Healthcare Conferences

Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy

Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy

Celyad to participate at upcoming healthcare conferences in September

Celyad to participate at upcoming healthcare conferences in September

Celyad Reports First Half 2018 Financial Results and Operational Progress

Celyad Reports First Half 2018 Financial Results and Operational Progress

Celyad Appoints Filippo Petti as Chief Financial Officer

Celyad Appoints Filippo Petti as Chief Financial Officer

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy